Ocelot's OCE-205 awarded US orphan drug designation for ascites

Dec. 21, 2023

The FDA has awarded orphan drug designation to Ocelot Bio Inc.'s lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer. Ocelot Bio plans to initiate clinical studies of OCE-205 in refractory ascites next year.

Today's news in brief

BioWorld

BioWorld briefs for May 7, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 5, 2026

The epidermal growth factor receptor in the inactive (left) and active (right) form.

Cytospire raises £61M series A to target EGFR in solid tumors

BioWorld

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...

Bio Korea 2026: US policy risks shift to execution framework

BioWorld

Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...

Regulatory actions for May 5, 2026

BioWorld

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...